WY-14643 (Pirinixic Acid): A Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective agonist for peroxisome proliferator-activated receptor alpha (PPARα), with an IC50 of 10.11 μM for human PPARα, enabling precise modulation of lipid metabolism and inflammation pathways (ApexBio). Aliphatic α-substitution on WY-14643 enhances dual PPARα/γ agonistic activity in the low micromolar range, broadening its translational utility. In cellular and animal models, WY-14643 down-regulates VCAM-1 expression, reduces monocyte adhesion, and improves whole-body insulin sensitivity without increasing body weight (Bao et al., 2025). The compound is insoluble in water but dissolves efficiently in DMSO and ethanol. WY-14643 is suitable for short-term solution use and must be stored at -20°C. These properties position WY-14643 as an essential reagent for metabolic disorder, inflammation, and tumor microenvironment research.

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate genes involved in lipid metabolism, glucose homeostasis, and inflammation. PPARα, predominantly expressed in liver, heart, kidney, and muscle, governs fatty acid oxidation and anti-inflammatory signaling (Bao et al., 2025). Dysregulation of PPARα pathways is implicated in metabolic disorders such as dyslipidemia, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Selective PPARα agonists like WY-14643 (Pirinixic Acid) serve as molecular tools to dissect PPAR signaling, enabling targeted studies of lipid metabolism regulation and TNF-α mediated inflammation. Recent multiomics research in tumor microenvironment modulation further underscores the relevance of PPARα activity in cancer biology (see related article—this article updates with new benchmarks on VCAM-1 and insulin sensitivity).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds selectively to the ligand-binding domain of PPARα, activating downstream transcriptional programs that upregulate genes involved in fatty acid transport, β-oxidation, and anti-inflammatory pathways. The compound’s IC50 of 10.11 μM for human PPARα denotes high potency (product page). Aliphatic α-substitution of WY-14643 increases agonist efficacy for both PPARα and PPARγ, yielding dual activity in the low micromolar range for balanced metabolic intervention. In Kupffer cells, WY-14643 moderately elevates hepatic TNFα mRNA, indirectly promoting hepatocyte mitogenesis. In endothelial cell models, pretreatment with 250 μM WY-14643 significantly down-regulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion, supporting its anti-inflammatory role (Bao et al., 2025).

Evidence & Benchmarks

• WY-14643 exhibits an IC50 of 10.11 μM for human PPARα, confirming high selectivity and potency (ApexBio).
• Aliphatic α-substitution augments dual PPARα/γ agonist activity in the low micromolar range, optimizing metabolic and inflammation pathway modulation (ApexBio).
• Pretreatment with 250 μM WY-14643 in endothelial cells significantly down-regulates TNF-α-induced VCAM-1 and reduces monocyte adhesion, demonstrating anti-inflammatory effects (Bao et al., 2025).
• Oral administration of 3 mg/kg/day WY-14643 for 2 weeks in high fat-fed rats lowers plasma glucose, triglycerides, leptin, muscle triglycerides, long-chain acyl-CoAs, and reduces visceral fat and liver triglyceride content, enhancing whole-body insulin sensitivity without increasing body weight (ApexBio).
• WY-14643 indirectly promotes hepatocyte mitogenesis by elevating hepatic TNFα mRNA levels through Kupffer cell activation (Bao et al., 2025).
• In multiomics tumor models, PPARα activation by ligands like WY-14643 modulates tissue factor (TF) expression, impacting tumor microenvironment and immune infiltration dynamics (Bao et al., 2025).

For a systems-biology perspective and translational discussion of these findings, see our advanced insights article; this present review adds new quantitative benchmarks and clarifies dual agonist parameters.

Applications, Limits & Misconceptions

WY-14643 is widely used to study metabolic disorders, lipid metabolism, inflammation, and tumor microenvironment regulation. Its dual PPARα/γ activity enables research into insulin sensitivity enhancement and anti-inflammatory agent action in endothelial cells. Caution is advised when extrapolating preclinical results to human pathology, as species differences in PPAR expression and ligand sensitivity exist.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: WY-14643 is for research use only; it is not approved for clinical or diagnostic applications (ApexBio).
• Water insolubility: The compound is insoluble in water; proper dissolution requires DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic-assisted).
• Short-term solution stability: Solutions are recommended for short-term use only due to stability considerations at room temperature or above.
• Species-specific effects: Rodent data may not fully reflect human metabolic or inflammatory responses due to interspecies differences in PPARα/γ expression and activation (Bao et al., 2025).
• Indirect mitogenic effects: Hepatocyte proliferation following WY-14643 exposure is indirect and mediated via Kupffer cell TNFα upregulation, not direct action on hepatocytes.

For a focused discussion on immunometabolic research boundaries, see our immunometabolic insights article; this present article clarifies solution use and anti-inflammatory benchmarks.

Workflow Integration & Parameters

Preparation and Storage: WY-14643 is provided as a solid, stored at -20°C. Dissolve in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic-assisted) for use. Water is not a suitable solvent. Prepare fresh solutions for immediate use; avoid repeated freeze-thaw cycles.

Cellular Assays: Effective concentrations range from 10 μM (PPARα activation) to 250 μM (VCAM-1/monocyte assays). Preincubate cells with WY-14643 for 1–4 hours at 37°C before stimulation.

Animal Studies: Oral dosing at 3 mg/kg/day over 2 weeks in high fat-fed rats is validated for metabolic endpoints. Monitor plasma glucose, triglycerides, leptin, and tissue lipid content. Avoid exceeding recommended doses to mitigate off-target effects.

Experimental Controls: Include vehicle (DMSO or ethanol) controls and, where relevant, dual agonists/antagonists for benchmarking. Quantify downstream gene expression (e.g., VCAM-1, TNFα mRNA) and metabolic parameters (e.g., acyl-CoAs, triglycerides).

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a validated, highly selective PPARα agonist with proven efficacy in modulating lipid metabolism, insulin sensitivity, and inflammation. Its dual PPARα/γ activity expands research potential in metabolic disorder and tumor microenvironment studies. While robust in preclinical models, researchers must account for species-specific responses and compound solubility. For comprehensive product specifications and ordering details, visit the A4305 kit product page.

This review synthesizes current evidence and parameters for experimental design and highlights boundaries of application. For advanced workflow strategies and translational perspectives, see our dual agonism deep-dive; this article offers updated solubility and benchmark guidance.